scispace - formally typeset
Journal ArticleDOI

Blood–Brain Barrier Transport of Kynurenines: Implications for Brain Synthesis and Metabolism

Reads0
Chats0
TLDR
The results demonstrate the saturable transfer of L‐KYN across the blood–brain barrier and suggest that circulating L‐ KYN, 3‐HKYN, and ANA may each contribute significantly to respective cerebral pools under normal conditions.
Abstract
To evaluate the potential contribution of circulating kynurenines to brain kynurenine pools, the rates of cerebral uptake and mechanisms of blood-brain barrier transport were determined for several kynurenine metabolites of tryptophan, including L-kynurenine (L-KYN), 3-hydroxykynurenine (3-HKYN), 3-hydroxyanthranilic acid (3-HANA), anthranilic acid (ANA), kynurenic acid (KYNA), and quinolinic acid (QUIN), in pentobarbital-anesthetized rats using an in situ brain perfusion technique. L-KYN was found to be taken up into brain at a significant rate [permeability-surface area product (PA) = 2-3 x 10(-3) ml/s/g] by the large neutral amino acid carrier (L-system) of the blood-brain barrier. Best-fit estimates of the Vmax and Km of saturable L-KYN transfer equalled 4.5 x 10(-4) mumol/s/g and 0.16 mumol/ml, respectively. The same carrier may also mediate the brain uptake of 3-HKYN as D,L-3-HKYN competitively inhibited the brain transfer of the large neutral amino acid L-leucine. For the other metabolites, uptake appeared mediated by passive diffusion. This occurred at a significant rate for ANA (PA, 0.7-1.6 x 10(-3) ml/s/g), and at far lower rates (PA, 2-7 x 10(-5) ml/s/g) for 3-HANA, KYNA, and QUIN. Transfer for KYNA, 3-HANA, and ANA also appeared to be limited by plasma protein binding. The results demonstrate the saturable transfer of L-KYN across the blood-brain barrier and suggest that circulating L-KYN, 3-HKYN, and ANA may each contribute significantly to respective cerebral pools. In contrast, QUIN, KYNA, and 3-HANA cross the blood-brain barrier poorly, and therefore are not expected to contribute significantly to brain pools under normal conditions.

read more

Citations
More filters
Journal ArticleDOI

Cerebrospinal fluid levels of kynurenine pathway metabolites in patients with eating disorders: Relation to clinical and biochemical variable

TL;DR: Cerebrospinal fluid levels of quinolinic acid, kynurenic acid, L-kynurenine, and 5-hydroxyindoleacetic acid were measured in medication-free female patients meeting DSM-III-R criteria for either anorexia nervosa or normal-weight bulimia nervosa, to determine whether the impaired nutrition characteristic of eating-disordered patients might be associated with specific disturbances in this metabolic pathway.
Journal ArticleDOI

Kynurenines in the Pathogenesis of Multiple Sclerosis: Therapeutic Perspectives.

TL;DR: This review considers various methods through which enzymes and metabolites of the kynurenine pathway influence the immune system, the roles they play in the pathogenesis of neuroinflammatory diseases based on current evidence with a focus on their involvement in multiple sclerosis, as well as therapeutic approaches.
Journal ArticleDOI

L-kynurenine: Metabolism and mechanism of neuroprotection

TL;DR: This review summarizes the main steps of the kynurenine pathway under normal conditions, discusses the metabolic disturbances and changes in this pathway in certain neurodegenerative disorders, and introduces the therapeutic applications of this pathway.
Journal ArticleDOI

Perinatal kynurenine pathway metabolism in the normal and asphyctic rat brain

TL;DR: The results revealed that the brain and liver content of L-KYN, KYNA and 3-HK is far higher pre-term than postnatally; KAT I and kynurenine 3-hydroxylase activities are quite uniform between E-16 and adulthood, whereas KAT II activity rises sharply after postnatal day 14.
Journal ArticleDOI

Role of Kynurenine Pathway in Oxidative Stress during Neurodegenerative Disorders.

TL;DR: In this paper, a review of the role of metabolites and enzymes of the kynurenine pathway in the development of oxidative damage within brain cells during neurodegenerative disorders and potential strategies that could reduce the severity of this process is presented.
References
More filters
Journal ArticleDOI

Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain

TL;DR: Intracerebral injection of the neuroexcitatory tryptophan metabolite, quinolinic acid, has behavioral, neurochemical and neuropathological consequences reminiscent of those of exogenous excitotoxins, such as kainic and ibotenic acids.
Journal ArticleDOI

Amino acid assignment to one of three blood-brain barrier amino acid carriers

TL;DR: Affinity for a basic amino acid carrier system was demonstrated for arginine, ornithine, and lysine and a third, low-capacity independent carrier system transporting aspartic and glutamic acids was demonstrated.
Journal ArticleDOI

An in situ brain perfusion technique to study cerebrovascular transport in the rat

TL;DR: The in situ brain perfusion technique is a sensitive new method to study cerebrovascular transfer in the rat and permits absolute control of perfusate composition.
Related Papers (5)